Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study

OBJECTIVES: The phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group SIRROUND-D study evaluated long-term efficacy and safety of the interleukin (IL)-6 inhibitor, sirukumab, in patients with active rheumatoid arthritis (RA) refractory to disease-modifying antirheumati...

Descripción completa

Detalles Bibliográficos
Autores principales: Thorne, Carter, Takeuchi, Tsutomu, Karpouzas, George Athanasios, Sheng, Shihong, Kurrasch, Regina, Fei, Kaiyin, Hsu, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269649/
https://www.ncbi.nlm.nih.gov/pubmed/30564449
http://dx.doi.org/10.1136/rmdopen-2018-000731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269649/
https://www.ncbi.nlm.nih.gov/pubmed/30564449
http://dx.doi.org/10.1136/rmdopen-2018-000731

Ejemplares similares